TNM分期与pN3a乳腺癌修订的必要性
该研究基于荷兰癌症登记处2005至2008年诊断为pN2a或pN3a的原发性浸润性上皮性乳腺癌患者数据,比较基于至少一个锁骨下淋巴结转移与≥10个腋窝淋巴结转移的pN3a患者预后差异。结果显示基于≥10个腋窝淋巴结转移的pN3a患者无病生存和总生存均劣于基于锁骨下淋巴结转移者,且基于锁骨下淋巴结转移的pN3a与pN2a预后相当。作者认为应考虑在下一版TNM分期中将锁骨下淋巴结转移重新分类为pN2a。
要点
- pN3a中仅4.6%(83例)基于至少一个锁骨下淋巴结转移,95.4%(1705例)基于≥10个腋窝淋巴结转移。
- 基于≥10个腋窝淋巴结转移的pN3a患者DFS 48.8% vs 基于锁骨下淋巴结转移者63.8%(HR 1.59,p=0.036)。
- 基于≥10个腋窝淋巴结转移的pN3a患者OS 46.6% vs 基于锁骨下淋巴结转移者63.9%(HR 1.46,p=0.042)。
核心结论
- 基于至少一个锁骨下淋巴结转移的pN3a状态罕见,但其预后优于基于≥10个腋窝淋巴结转移的pN3a。
- 作者认为应考虑在下一版TNM分期中将锁骨下淋巴结转移重新分类为pN2a。
研究设计与样本
- 数据来自荷兰癌症登记处,纳入2005至2008年诊断为原发性浸润性上皮性乳腺癌且病理结果为pN2a或pN3a的患者。
- pN3a患者被细分为基于至少一个锁骨下淋巴结转移或基于≥10个腋窝淋巴结转移两组。
- 共纳入3400例pN2a患者和1788例pN3a患者。
主要发现
- pN3a患者中83例(4.6%)基于至少一个锁骨下淋巴结转移,1705例(95.4%)基于≥10个腋窝淋巴结转移。
- 多变量分析后,基于≥10个腋窝淋巴结转移的pN3a患者DFS为48.8%,基于锁骨下淋巴结转移者为63.8%(HR 1.59,p=0.036)。
- 多变量分析后,基于≥10个腋窝淋巴结转移的pN3a患者OS为46.6%,基于锁骨下淋巴结转移者为63.9%(HR 1.46,p=0.042)。
- 基于锁骨下淋巴结转移的pN3a与pN2a患者的DFS和OS相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. METHODS: Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan-Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. RESULTS: A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. CONCLUSION: PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.
引用
- van Nijnatten TJA, Moossdorff M, de Munck L, et al. TNM classification and the need for revision of pN3a breast cancer. Eur J Cancer. 2017. PMID: 28458119. doi:10.1016/j.ejca.2017.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。